10-Q: Femasys Reports Q3 2026 Results, Faces Net Loss Amidst Financing Efforts

Femasys Inc. filed its Q3 2026 10-Q, detailing a net loss of $4.56 million, increased R&D and G&A expenses, and significant cash burn, while also highlighting a substantial private placement to fund operations and product development.

Summary

• Femasys Inc. reported a net loss of $4,564,815 for the third quarter ended September 30, 2026, compared to a net loss of $4,194,821 in the same period last year.
• Total operating expenses increased by 14.1% to $4,667,111 for Q3 2026, driven by higher research and development (R&D) and general and administrative (G&A) costs.
• Sales for the quarter decreased by 44.5% to $404,597, primarily due to a decline in international FemBloc orders.
• The company ended the quarter with $23,913,946 in cash and cash equivalents, which management believes is sufficient for at least the next twelve months.
• A significant private placement in August 2026 raised approximately $27.4 million in net proceeds, with potential for an additional $55.3 million upon warrant exercise.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, increased operating expenses, and substantial outstanding debt and potential dilution from convertible notes and warrants, despite positive developments in product commercialization and financing.

Positives

• The company ended the quarter with a healthy cash balance of $23,913,946, which is expected to fund operations for at least the next twelve months.
• A substantial private placement in August 2026 raised $27.4 million in net proceeds, with potential for up to $55.3 million more upon warrant exercise, bolstering liquidity.
• FemaSeed, FemVue, FemCerv, and FemChec products continue to be commercialized in the U.S. and international markets.
• The company received FDA approval for the modular premarket approval (PMA) pathway for FemBloc.
• Partnerships with UNC Health, CapexMD, Minnesota Womens Care, and SandsRx Pharmacy were established to expand patient access and support product launches.
• The company announced the doubling of actively enrolling sites for its FemBloc FINALE trial to twelve.

Negatives

• The company reported a net loss of $4,564,815 for Q3 2026, an increase from the prior year's Q3 loss of $4,194,821.
• Total operating expenses increased by 14.1% to $4,667,111 in Q3 2026, primarily due to higher R&D and G&A expenses.
• Sales decreased by 44.5% to $404,597 in Q3 2026 compared to the prior year, largely due to a decline in international FemBloc orders.
• The company has a significant accumulated deficit of $154,013,954 as of September 30, 2026.
• There is a substantial risk of dilution to existing stockholders due to outstanding convertible notes and warrants, with potential for over 4.1 million shares to be issued.
• The company faces litigation from Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC seeking approximately $3.1 million related to its 2025 Notes.

Risks

• The company may not have sufficient funds to satisfy payment obligations under its convertible notes at maturity in November 2035.
• Conversion of convertible notes could result in significant dilution of common stock and a decline in market price.
• The ongoing litigation with Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC could result in substantial cash payments and divert management attention.
• The company's ability to continue as a going concern is dependent on its ability to secure additional financing.
• The company may need to terminate, modify, or delay development of its U.S. product candidate, FemBloc, if it cannot secure adequate additional capital.
• The company's capital structure gives rise to a significant and compounding risk of dilution to existing stockholders from convertible notes and warrants.
• The milestone warrants issued in the August 2026 financing have conditions that, if not met, could accelerate their expiration.

Future Outlook

The company expects to continue investing in commercialization and clinical development, anticipating ongoing operating losses and cash utilization. Management believes current cash and cash equivalents are sufficient for at least the next twelve months, but additional capital may be required to complete FemBloc development and commercialization.

Management Comments

• The company believes that its cash and cash equivalents as of September 30, 2026 will provide sufficient liquidity to fund its planned operations, capital requirements, and other obligations for at least the twelve-month period following the issuance of these condensed financial statements.
• We expect to continue to make substantial investments in our ongoing commercialization of our products and the pivotal trial that is designed to provide clinical evidence of the safety and effectiveness of our U.S. product candidate, FemBloc.
• Because of these and other factors, we expect to continue to incur substantial net losses and negative cash flows from operations for the foreseeable future.

Industry Context

StockSavvy.ai notes that Femasys operates in the competitive women's health sector, focusing on fertility and permanent birth control solutions. The company's strategy involves developing in-office, non-surgical alternatives to traditional methods, aiming to reduce costs and improve patient outcomes. The recent financing and partnerships indicate efforts to scale commercialization and advance key product candidates like FemBloc through regulatory hurdles.

Comparison to Industry Standards

• Femasys's net loss of $4.56 million for Q3 2026, while significant, is within the range of early-stage biotech companies investing heavily in R&D and clinical trials.
• The company's revenue of $404,597 for Q3 2026 is modest, reflecting the early commercialization stage of its products, particularly compared to established players in the broader women's health market.
• The substantial increase in R&D expenses (40.6% year-over-year for Q3) aligns with industry norms for companies advancing novel medical devices through clinical trials and regulatory approvals, such as the FemBloc pivotal trial.
• The company's cash burn rate, while high, is typical for pre-revenue or early-revenue stage medical device companies requiring significant capital for product development and market entry.

Management Changes

Legal Proceedings

• Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC filed a motion for summary judgment seeking approximately $3.1 million plus interest and attorneys fees, alleging that the Company's August 7, 2026 Securities Purchase Agreement constituted a Fundamental Transaction under the 2025 Notes.

Related Party Transactions

• In November 2023, PharmaCyte Biotech, Inc. (PharmaCyte) was issued a $5 million convertible note and warrants. In November 2025, the Company paid PharmaCyte accrued interest in equity.
• In June 2025, certain executive officers and a director purchased shares in a private placement at a higher price ($20.40) than other investors ($17.00).
• In August 2025, certain executive officers purchased common shares and warrants at the market price.
• In November 2025, certain executive officers and directors purchased convertible notes and warrants, with $175,000 in notes and accrued interest of $13,346 due as of September 30, 2026.
• In August 2026, certain officers purchased shares and warrants on the same terms as other purchasers in the private placement.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of convertible notes and exercise of warrants.
• The ongoing litigation could negatively impact the company's financial condition and ability to fund operations, potentially affecting shareholder value.
• The company's ability to continue as a going concern is dependent on future financing, posing a risk to investors.
• Employees may be impacted by potential delays or termination of development activities if sufficient capital is not raised.

Next Steps

• Advance commercialization of FemaSeed fertility portfolio.
• Conduct FemBloc pivotal trial to support U.S. approval.
• Continue to invest in research and development for future products.
• Expand sales and marketing organization for FemaSeed and FemBloc.
• Monitor and manage cash burn and pursue additional financing if necessary.

Key Dates

Recommendation

The company shows promise with its product pipeline and recent financing, but the significant net losses, increasing expenses, substantial debt, and high risk of dilution from outstanding convertible notes and warrants warrant a cautious approach. While the cash position is adequate for the near term, the path to profitability and successful commercialization of FemBloc remains uncertain and capital-intensive, suggesting a 'hold' recommendation pending clearer signs of financial stability and revenue growth.

Keywords

Femasys, 10-Q, Quarterly Report, FemBloc, FemaSeed, Fertility, Birth Control, Biomedical